Classic Galactosemia

Immediate steps for primary care clinicians receiving a newborn’s positive screen result

Introduction

Classic galactosemia is an inborn error of carbohydrate metabolism caused by a severe deficiency of the galactose-1-phosphate uridylyltransferase (GALT) enzyme, which disrupts the body’s ability to metabolize the sugar galactose. This block in the Leloir pathway leads to the rapid toxic accumulation of galactose-1-phosphate, galactose, and galactitol following the ingestion of breast milk or lactose-containing formula. Neonates typically present within the first few days of life with life-threatening symptoms, including poor feeding, vomiting, profound jaundice, hepatomegaly, and a high susceptibility to Escherichia coli neonatal sepsis. Acute symptoms respond well to dietary restriction of lactose, but individuals remain at a high risk for long-term complications, including developmental delays, speech dyspraxia, ataxia, and premature ovarian insufficiency (POI) in females. While variant forms of galactosemia (such as Duarte variant) and other types caused by galactokinase (GALK) or uridine diphosphate galactose-4-epimerase (GALE) deficiencies exist, they represent separate clinical entities not addressed in this article.

Other names: GALT deficiency, Galactose-1-phosphate uridylyltransferase deficiency, Galactosemia type 1

Keywords: Galactose, galactosemia, lactose, liver failure, inborn error of metabolism, newborn screening, primary ovarian insufficiency

Disorder Category

Galactosemia

Abnormal Finding

Deficiency of galactose-1-phosphate uridylyltransferase (GALT) enzyme activity

Tested By

Semiquantitative, fluorometric GALT enzyme assay

Results may be compromised by excess heat exposure to the sample, resulting in a false positive, or compromised by transfusion prior to specimen collection, resulting in a false negative.

Clinical Characteristics

For classic galactosemia, symptoms develop shortly after ingestion of milk or other lactose-containing products. In most cases, this will occur before newborn screening results are available as a life-threatening emergency in a neonate presenting with poor feeding, vomiting, profound jaundice, hepatomegaly, and bleeding diathesis.

With treatment, life-threatening acute metabolic complications can be prevented. However, despite early and adequate therapy, a significant subset of individuals with classic galactosemia will still experience long-term neurodevelopmental complications. These include speech defects (predominantly childhood apraxia of speech), cognitive impairments, and progressive neurological deficits such as ataxia, tremors, and extrapyramidal findings. Additionally, premature ovarian insufficiency (POI) develops in the vast majority of females, severely compromising fertility, though rare instances of spontaneous or assisted conception have occurred. In contrast, males generally exhibit normal pubertal development and preserved fertility, though some can demonstrate abnormalities in semen parameters.

Without treatment, ingestion of lactose leads to rapid clinical deterioration and a high risk of neonatal mortality.

Initial signs/symptoms of galactosemia may include:

  • Poor feeding
  • Vomiting
  • Diarrhea
  • Jaundice
  • Bleeding diathesis
  • Lethargy
  • Hepatomegaly
  • Failure to thrive
  • Increased risk of sepsis with gram-negative organisms

If not treated promptly (first 7 days of life), patients may experience:

  • Progressive liver failure
  • Severe brain damage
  • Death

Incidence

Classic galactosemia occurs in about 1 in 30,000 live births; Duarte variant occurs in about 1 in 16,000.1 

Inheritance

Autosomal recessive – Genetic testing is possible for at-risk family members if both disease-causing mutations of an affected family member have been identified.

Next Steps After a Positive Screen

  • Contact the family and evaluate the infant for related symptoms.
  • Provide same-day emergency treatment and referral to Biochemical Genetics (Metabolics) for any symptoms of poor feeding, lethargy, jaundice, bleeding, bulging fontanel, and vomiting. Severity may be screened rapidly with liver function tests (LFTs), prothrombin time with international normalized ratio (PT/INR), and urine reducing substance assay.
  • Discontinue all breastmilk and lactose-containing formula feeds. Start soy formula (e.g., Prosobee or Isomil) feeds immediately.
  • Patients with a positive screening test or who are symptomatic should be on a lactose/galactose-free diet until GALT enzyme activity and galactosemia DNA panel results are available.

Confirming the Diagnosis

  • To confirm the diagnosis, work with Newborn Screening Services.
  • Follow-up testing will involve galactose-1-phosphate uridyltransferase activity, red cell Gal-1-P, and GALT gene sequencing.
    • In classic galactosemia, GALT activity is absent or barely detectable, and Gal-1-P is markedly elevated.
    • Clinical variant galactosemia tends to have less remarkable elevations of Gal-1-P or, in some cases, may even be in the normal range, but GALT activity will still be significantly reduced to ~1%.
    • With biochemical variant (e.g., Duarte) or carrier status, the GALT activity is moderately reduced to approximately 25% or greater compared to controls and Gal-1-P range from normal to mildly elevated.

If the Diagnosis is Confirmed

  • For evaluation and ongoing collaborative management, consult Medical Genetics.
  • Refer the family to Genetic Testing and Counseling.
  • If the galactose-1-phosphate uridyltransferase and/or the GALT gene sequencing are consistent with classical galactosemia (GG genotype with low activity level), dietary restriction of galactose should continue. Patients with Duarte galactosemia do not require dietary restrictions. In Duarte galactosemia, the galactose-1-phosphate level may be elevated in the first year of life, but no deficits occur.
  • Educate the family about the signs, symptoms, and the need for urgent care when the infant becomes ill.
  • Assist in implementing and maintaining a rigid dietary exclusion of lactose and galactose.
  • Monitor for developmental delays, speech delay, and, in females, ovarian failure.
  • Assist in the patient’s developmental management, particularly with developmental and educational interventions as needed.

References

1. Therrell BL, Lloyd-Puryear MA, Camp KM, Mann MY. Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab. 2014;113(1-2):14-26. doi:10.1016/j.ymgme.2014.07.009

2. Freer DE, Ficicioglu C, Finegold D. Newborn screening for galactosemia: a review of 5 years of data and audit of a revised reporting approach. Clin Chem. 2010;56(3):437-444. doi:10.1373/clinchem.2009.135947

Article History

This article was originally published on the Medical Home Portal and updated before publication on TRiP. The Medical Home Portal, retired in July 2024, provided diagnosis and management information for pediatric conditions, guidance for immediate steps after a positive newborn screen result, and in-depth family education to improve outcomes for children with complex medical care needs. The full archive can be found at the Medical Home Portal Archive. 

Topical Reviews in Pediatrics (TRIP) includes archival and updated content from the Medical Home Portal and features new, contemporary topics in pediatrics.   

  • 2022 revision: Brian Shayota, MDA
  • 2012 revision: Kimberly Hart, MS, LCGCA
  • 2007 first publication: Nicola Longo, MD, PhDA

AAuthor; CAContributing Author; SASenior Author; RReviewer

Brian J. Shayota, MD, MPH

Dr. Shayota completed his medical degree at St. George’s University, School of Medicine. He then completed a Pediatric residency at New York Medical College in Paterson, NJ, and a Medical Genetics residency and Medical Biochemical fellowship at Baylor College of Medicine. Dr. Brian Shayota is an Associate Professor of Pediatrics and Medical Genetics at the University of Utah/Primary Children's Hospital. He is also the Director of Metabolic Services, Director of the Telegenetics Consultation Services offered to Level III NICUs throughout Utah, and Director of the ReSeq clinic.

Dr. Shayota’s career has focused on caring for patients with rare inborn errors of metabolism and discovering new/rare genetic conditions. Dr. Shayota is particularly interested in identifying new therapeutic approaches to rare genetic disorders, including service as the primary investigator on several clinical trials using novel treatments like gene therapy in human trials. He is also the lead metabolic specialist reviewing newborn screens for the states of Utah, Nevada, and Alaska. He is passionate about expanding access to genetic services in rural communities and creating innovative public health programs that place the interests of the patient and their family first.

No conflicts of interest to report

View more for →

Stay Informed